| Title | New endocrine therapies for oestrogen-dependent breast cancer | |
| Author | George Assimakopoulos
Breast Cancer Unit, Iaso Maternity Hospital, Athens, Greece |
|
| Citation | Assimakopoulos, G.: New endocrine therapies for oestrogen-dependent breast cancer, Epitheorese Klin. Farmakol. Farmakokinet. 12(3): 91-100 (1998) | |
| Publication Date | Received for publication: 20 October 1998
Accepted for publication: 10 November 1998 |
|
| Full Text Language | English | |
| Order – Buy | Ηλεκτρονική Μορφή: pdf (10 €) – Digital Type: pdf (10 €)
pharmakonpress[at]pharmakonpress[.]gr |
|
| Keywords | Breast cancer, early, advanced, metastatic, endocrine therapy, anti-oestrogens, LHRH analogues, progestins, anti-progestins, aromatase inhibitors. | |
| Other Terms | review article | |
| Summary | Endocrine therapy for breast cancer has a long history, dating from the last years of the past century. Today, endocrine therapy is classified in four types: (a) surgical or medical castration by LHRH analogues (such as goserelin), (b) anti-oestrogens non-steroidal derivatives of triphenylethylene (mainly tamoxifen) and steroidal derivatives of oestradiol (ICI 182,780), (c) progestins and (d) aromatase inhibitors, steroidal (formestane, exemestane) and non-steroidal (such as fadrozole, letrozole, anastrozole). Anti-oestrogens act by competitively blocking the oestrogen receptors (ER); LHRH analogues act on the hypothalamic-pituitary axis to suppress ovarian function, decreasing luteinising hormone and oestradiol levels to post-menopausal values; aromatase inhibitors are characterised by their capacity to decrease the level of circulating oestrogen and by their selective anti-aromatase action which avoid using corticoids. Data from different trials demonstrated an objective response rate for goserelin, 3.6 mg, of 36.4% in premenopausal and perimenopausal patients with advanced breast cancer. Preliminary results in premenopausal women with early breast cancer indicate that endocrine treatment with goserelin plus tamoxifen may be as effective as standard combination chemotherapy, but has significantly less acute toxicity. Tamoxifen is widely used in the treatment of early breast cancer and as first-line endocrine therapy in metastatic disease. In advanced breast cancer, response rates of up to 60% in women with ER+ tumours have been reported. In early breast cancer, tamoxifen can produce significant benefits in terms of reduction in relative risk of relapse or death in all patients’ subgroups except premenopausal women with ER- tumours. The major benefit is seen in women over 50 years old with ER+ tumours. The results of randomised trials suggest that the optimum duration of tamoxifen therapy is at least 5 years. Phase II trials indicated that formestane has comparable activity to other endocrine treatments, white phase III trials have shown that its efficacy matches that of both tamoxifen and megestrol acetate when used as first and second-line endocrine therapy, with 54% and 51% of patients with advanced breast cancer achieving either objective response or stable disease. Overall survival was also similar. The systemic tolerability of formestane is comparable to that of tamoxifen and better than that of megestrol acetate. Letrozole, in two phase II studies, was shown to be an effective new treatment; in a phase ill trial, letrozole 2.5 mg once daily was shown to be more effective and better tolerated than megestrol acetate in the treatment of postmenopausal women with advanced breast cancer previously treated with anti-oestrogens. In two phase III studies, Anastrozole 1 mg and 10 mg once daily were compared with megestrol acetate. The lower dose was sufficient to suppress serum oestradiol to below the detection limit of the assay used. Both trials were performed in patients who had failed tamoxifen and who had ER- or ER unknown tumors; the results of both trials were identical and there were no significant differences in response rates between the two doses or between either dose of anastrozole and megestrol acetate. The once a day dosing and lack of weight gain with anastrozole make it more attractive than megestrol acetate for treatment of patients failing therapy with tamoxifen. None of the second and third generation aromatase inhibitors in trial have the toxicity associated with aminoglutethimide. The major side-effects are mild gastrointestinal disturbance and hot flushes in approximately 40% of patients. | |
| References | 1. Dowsett M.: Rationale for the endocrine treatment of breast cancer. In: Endocrine Aspects of Breast Cancer (M. Dowsett, ed.). pp. 11-24, Parthenon, Camforth, 1992
2. Femara (letrozole). Novartis Pharma AG, Basle, 1997 3. Howeli A., DeFriend D., Anderson E.: Mechanisms of response and resistance to endocrine therapy for breast cancer and the development of new treatments. Rev. Endocr.- Rel. Cancer 43: 5-21 (1993) 4. Μουτσάτσου Π., Σέκερης Κ.: Μηχανισμός δράσης των στεροειδών ορμονών. Επιθεώρηση Κλινικής Φαρμακολογίας και Φαρμακοκινητικής 14: 75-80 (1996) 6. Bhatnagar A.S., Hausler A., Schteweck Κ. et al.: Estrogen depletion in advanced breast cancer: why, how and where are going? In: Advanced Breast Cancer; reassessing hormonal therapy. Volume 2, pp. 21-30, Ciba International Symposium Series, The Parthenon Publishing Group, London, 1996 7. Beatson G.T.: On the treatment of inoperable cases carcinoma of the mamma. Suggestions for a new method of treatment with illustrative cases. Lancet II: 104-107 (1896) 8. Henderson I.C., Harris J.R.: Principles in the management of metastatic disease. In: Breast Disease (J.R. Harris, S. Heilman, I.C. Henderson, D.W. Kinne, eds), 2nd Ed., p. 547, Lippincott, Philadelphia, 1991 9. Kaufmann M.: Update on endocrine approaches in the treatment and prevention of breast cancer. Eur. J. Cancer 34 (Suppl. 5): S81 (1998) 10. Howell A., Downey S., Anderson E.: New endocrine therapies for breast cancer. Eur. J. Cancer 32A: 576-588 (1996) 11. Howell A., DeFriend D., Anderson E.: Mechanisms of response and resistance to endocrine therapy for breast cancer and the development of new treatments. Rev. Endocr.-Rel. Cancer 43: 5-21 (1993) 12. Early Breast Cancer Trialist’s Collaborative Group: Tamoxifen for early breast cancer: an overview of the randomised trials. Lancet 351: 1451-1467 (1998) 13. Swedish Breast Cancer Cooperative Group: Randomized trial of two versus five years of adjuvant tamoxifen for postmenopausal early stage breast cancer. J. Nad. Cancer Inst. 88: 1543-1549 (1996) 14. Fisher B., Dignam J., Wolmark N., et al.: Tamoxifen and chemotherapy for lymph node-negative, estrogen receptor-positive breast cancer. J. Natl. Cancer Inst. 89: 1673-1682 (1997) 15. International Breast Cancer Study Group: Effectiveness of adjuvant chemotherapy in combination with tamoxifen for node-positive postmenopausal breast cancer patients. J. Clin. Oncol. 15: 1385-1394 (1997) 16. Jordan V.C., Glusman J.E., Eckert S., et al.: Incident primary breast cancer are reduced by raloxifene: integrated data from multicenter, double-blind, randomized trials in 12,000 postmenopausal women. Proc. Am. Soc. Clin. Oncol. 17: 122a (1998) 17. Cummings S.R., Norton L.( Eckert S., et al.: Raloxifene reduces the risk of breast cancer and may decrease the risk of endometrial cancer in post-menopausal women. Two-year findings from the multiple outcomes of raloxifene evaluation. Proc. Am. Soc. Clin. Oncol. 17: 2a (1998) 18. Howell A., Osborne C.K., Morris C.Q., Dimery I.: Breast cancer clinical trials with Faslodex – A new class of antioestrogen. Eur. J. Cancer 34 (Suppl. 5): S19 (1998) 19. Taylor C.W., Green S., Dalton W.S., et al.: Multicenter randomized trial of Goserelin versus surgical ovariectomy in premenopausal patients with receptor-positive metastatic breast cancer. J. Clin. Oncol. 16: 994-999 (1998) 20. Jonat W.: Luteinizing hormone-releasing hormone analogues – the rationale for adjuvant use in premenopausal women with early breast cancer. Br. J. Cancer 78(Suppl. 4): 5-8 (1998) 21. Klijn J.G.M., Beex L., Mauriac L., et al.: Combined treatment with the LHRH-agonist buserelin (LHRH-A) and tamoxifen (TAM) vs single treatment with each drug alone in premenopausal metastatic breast cancer. Final results of EORTC study 10881. Ann. Oncol. 9 (Suppl. 4): 11 (1998) 22. Boccardo F., Rubagotti A., Amoroso D. et al.: CMF versus tamoxifen plus goserelin as adjuvant treatment of ER positive pre-perimenopausal breast cancer patients. Preliminary results of the GROCTA 02 study. Proc. Am. Soc. Clin. Oncol. 17: 99a (1998) 23. Williams C.L., Stancel G.M.: Estrogens and progestins. In: Goodman and Gilman’s The Pharmacological Basis of Therapeutics (J.G. Hardman, L.E. Limbird, eds), 9th Ed., pp. 1411-1440, McGraw-Hill, New York, 1996 24. Namer M., Ramaioli A.: Les nouveaux inhibiteurs de l’aromatase dans le traitement du carcer du sein metastatique. Med. Hyg. 56: 1527-1531 (1998) 25. Assimakopoulos G.: Treatment of breast metastatic cancer: New aromatase inhibitors. Epitheor. Kiln. Farmakol. Farmakokinet. Creek Ed. 16: 53-72 (1998) 26. Miller W.L.: Molecular biology of steroid hormone synthesis. Endocr. Rev. 9: 295-318 (1998) 27. Miller W.L.: The clinical relevance of aromatase activity in breast tumour tissue. In: Aromatase Inhibition: Present and Future (W. Jonat, R.J. Santen, eds), pp. 37-46, Carnforth: Parthenon, 1991 28 Wiseman L.R., Goa K.L.: Formestane. A review of its pharmacological properties and clinical efficacy in the treatment of mostmenopausal breast cancer. Drugs Aging 9: 292-306 (1996) 29. Jones S., Vogel C., Fehrenbacher L., et al.: A phase II study of antitumor efficacy and safety of exemestane (EXE) as third-line hormonal treatment of postmenopausal patients with metastatic breast cancer (MBC) refrastory to tamixifen and MegaceTM. Ann. Oncol. 9 (Suppl. 4): 13-14 (1998) 30. Chabner B.A., Allegra C.J., Curt G.A., Calabresi P.: Antineoplastic agents. In: Goodman and Gilman’s The Pharmacological Basis of Therapeutics (J.G. Hardman, L.E. Limbird, eds), 9th Ed., pp. 1233-1287, McGraw-Hill, New York, 1996 31. Thurlimann B., Beretta K., Bacchi M., et al.: First line fadrozole HCl (CGS 16949A) versus tamoxifen (TAM) in advanced breast cancer: prospective randomised study SAKK 20/80. Proc. Am. Soc. din. Oncol. 14: 98 (Abstr. No 90) (1995) 32. Johnston S.R.D., Smith I.E., et al.: Clinical and endocrine effects of the oral aromatase inhibitor vorozole in postmenopausal patients with advanced breast cancer. Cancer Res. 54: 5875-5880 (1994) 33. Iveson T.J., Smith I.E., Ahern J., et al.: Phase I study of the oral nonsteroidal aromatase inhibitor CGS 20267 in postmenopausal patients with advanced breast cancer. Cancer Res. 53: 266-270 (1993) 34. Lipton A., Demers L.M., Harvey H.A., et al.: Letrozole (CGS 20267). A phase I study of a new potent oral aromatase inhibitor of breast cancer. Cancer 75: 2132-2138 (1995) 35. Schultz J., Fox K., Conner G., et al.: A phase II study of rogletimide (ROG) in females with ad-vanced/metastatic breast cancer (A/M BrCa). Proc. Am. Soc. Clin. Oncol. 14: 93 (Abstr. No 73) (1995) 36. Harnett A.N., Canney P., Coombes R.C., et al.: A randomised phase II trial of rogletimide in heavily pretreated breast cancer patients. Proc. Am. Soc. Clin. Oncol 14: 176 (Abstr. No 388) (1995) 37. Dombernowsky P., Smith I., Falkson G., et al.: Letrozole, a new oral aromatase inhibitor for advanced breast cancer: Double-blind randomized trial showing a dose effect and improved efficacy and tolerability compared with megestrol acetate. J. Clin. Oncol. 16: 453-461 (1998) 38. Gershanovich M., Chaudri H.A., Campos D., et al.: Letrozole, a new oral aromatase inhibitor: Randomized trial comparing 2.5 mg daily and aminoglutethimide in postmenopausal women with advanced breast cancer. Ann. Oncol. 9: 639-645 (1998) 39. Buzdar A., Jonat W., Howell T., et al.: Anastrozole, a potent and selective aromatase inhibitor, versus Megestrol Acetate in postmenopausal women with advanced cancer: Results of overview analysis of 2 phase III trials. J. din. Oncol. 14: 2000-2011 (1996) 40. Buzdar A., Jonat W., Howell T., et al.: Significant improved survival with Arimidex vs Megestrol Acetate in post-menopausal advanced breast cancer: Updated results of two randomized trials. Pro. ASCO, 1997 41. Buzdar A.U., Jonat W., Howell A., et al.: Anastrozole versus megestrol acetate in the treatment of postmenopausal women with advanced breast cancer. Results of a survival update based on a combined analysis of data from two mature phase III trials. Cancer 83: 1142-1152 (1998) |
|
| Relative Papers |
Online ISSN 1011-6575
Άρθρα Δημοσιευμένα σε αυτό το Περιοδικό Καταχωρούνται στα:
- Chemical Abstracts
- Elsevier’s Bibliographic Databases: Scopus, EMBASE, EMBiology, Elsevier BIOBASE SCImago Journal and Country Rank Factor
Articles published in this Journal are Indexed or Abstracted in: • Chemical Abstracts • Elsevier’s Bibliographic Databases: Scopus, EMBASE, EMBiology, Elsevier BIOBASE SCImago Journal and Country Rank Factor
Συντακτικη Επιτροπή-Editorial Board
| ΕΤΗΣΙΑ ΣΥΝΔΡΟΜΗ 1998 – ANNUAL SUBSCRIPTION 1998 | |
| Γλώσσα Πλήρους Κειμένου – Full Text Language | Αγγλικά, Γαλλικά – English, French |
| Παραγγελία – Αγορά – Order – Buy | Ηλεκτρονική Μορφή: pdf (70 €) – Digital Type: pdf (70 €)
pharmakonpress[at]pharmakonpress[.]gr |
| Έντυπη Μορφή (70 € + έξοδα αποστολής) – Printed Type (70 € + shipping)
pharmakonpress[at]pharmakonpress[.]gr |
|